The Role of Cytokines which Signal through the Common γ Chain Cytokine Receptor in the Reversal of HIV Specific CD4+ and CD8+ T Cell Anergy
Open Access
- 21 March 2007
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 2 (3) , e300
- https://doi.org/10.1371/journal.pone.0000300
Abstract
HIV specific T cells are putatively anergic in vivo. IL-2, a member of a class of cytokines that binds to receptors containing the common gamma chain (γc) has been shown to reverse anergy. We examined the role of γc cytokines in reversing HIV specific T cell anergy. PBMC from untreated HIV-infected individuals were briefly exposed to a panel of γc cytokines, and frequencies of gag specific T cells were enumerated by intracellular IFN-γ flow cytometry. Of the γc cytokines, brief exposure to IL-2, IL-15, or combined IL-15/IL-7 significantly enhanced (range 2–7 fold) the CD4+ and CD8+ T cell IFN-γ responses to HIV gag, with IL-15 giving the greatest enhancement. The effects of cytokines were not due to enhanced proliferation of pre-existing antigen specific cells, but were due to a combination of enhanced cytokine production from antigen specific T cells plus activation of non-epitope specific T cells. These observations support the notion that a significant number of HIV specific T cells are circulating in an anergic state. IL-2, IL-7 and particularly IL-15 as an immune modulator to reverse HIV-1 specific T cell anergy should be investigated, with the caveat that non-specific activation of T cells may also be induced.Keywords
This publication has 39 references indexed in Scilit:
- HIV-1 Viremia Prevents the Establishment of Interleukin 2–producing HIV-specific Memory CD4+ T Cells Endowed with Proliferative CapacityThe Journal of Experimental Medicine, 2003
- Persistent numbers of tetramer+ CD8+ T cells, but loss of interferon-γ+ HIV-specific T cells during progression to AIDSBlood, 2002
- Pilot Study of the Effects of Intermittent Interleukin‐2 on Human Immunodeficiency Virus (HIV)–Specific Immune Responses in Patients Treated during Recently Acquired HIV InfectionThe Journal of Infectious Diseases, 2002
- Efficacy of Low‐Dose Subcutaneous Interleukin‐2 to Treat Advanced Human Immunodeficiency Virus Type 1 in Persons with ⩽250/μL CD4 T Cells and Undetectable Plasma Virus LoadThe Journal of Infectious Diseases, 1999
- Characterization of HIV-1-specific T-helper cells in acute and chronic infectionImmunology Letters, 1999
- Serum Cytokine Profiles in Acute Primary HIV-1 Infection and in Infectious MononucleosisClinical Immunology and Immunopathology, 1996
- The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virusEuropean Journal of Immunology, 1995
- Primary Human Immunodeficiency Virus Type 1 Infection: Review of Pathogenesis and Early Treatment Intervention in Humans and Animal Retrovirus InfectionsThe Journal of Infectious Diseases, 1993
- Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis.The Journal of Experimental Medicine, 1992
- lnterleukin-2 programs mouse αβ T lymphocytes for apoptosisNature, 1991